Results 191 to 200 of about 227,240 (251)

Case Report: Immune checkpoint inhibitor-associated pulmonary hypertension. [PDF]

Front Cardiovasc Med
Yuan S, Hu X, Zhao Y, Dai H.
europepmc   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

Enhancing immunogenic cell death by targeting the GPX4-ZP3 immune checkpoint. [PDF]

Oncoimmunology
Tang D, Kang R, Liu P, Kroemer G.
europepmc   +1 more source

Targeting PRKCN, an Essential Driver Orchestrating mTOR‐IRF4 Axis Independently of Kinase Activity, in Multiple Myeloma

Advanced Science, EarlyView.
Constitutive PRKCN expression is driven by super‐enhancers and modulated by NF‐κB signaling in multiple myeloma (MM). PRKCN activates mTORC1/2‐IRF4 signaling axis and favors tumor cell growth independently of its kinase activity. IRF4 reciprocally promotes PRKCN transcription, creating a feed‐forward loop.
Koukou Tang, Dongpeng Jiang, Peng Ke, Xiaosen Bian, Lili Zhang, Ying Zhang, Tingting Zhu, Weiwei Qu, Wenhui Qi, Yang Xu, Chengcheng Fu, Depei Wu, Jianhong Chu   +12 more
wiley   +1 more source

Radiotherapy plus immune checkpoint inhibitors versus immune checkpoint inhibitors alone for non-small cell lung cancer with bone metastases: a systematic review and meta-analysis of comparative cohort studies. [PDF]

Front Immunol
Ruan Y, Cao W, Long C, Guo S, Han J, Chen Z, Zhang T.   +6 more
europepmc   +1 more source

NK Cell Activation by Platinum Boosts Immunotherapy in HR+/HER2− Breast Cancer

Advanced Science, EarlyView.
Multi‐omics and single‐cell analyses identify activated NK cells as key mediators of anti‐PD‐(L)1 response in HR+/HER2− breast cancer. Platinum chemotherapy enhances NK cell cytotoxicity through NF‐κB–associated signaling, synergizing with immunotherapy and providing a rationale for combination treatment.
Yi‐Yu Chen, Yi‐Fan Zhou, Xuan Qi, Ya‐Xin Zhao, Tong Fu, Xi Jin, Minhong Shen, Yi‐Zhou Jiang, Zhi‐Ming Shao   +8 more
wiley   +1 more source

BTLA: An Emerging Immune Checkpoint Target in Cancer Immunotherapy. [PDF]

Pharmaceuticals (Basel)
Chang MC, Lee WC, Tai YJ, Chiang YC.
europepmc   +1 more source

Decoding the Cardiac Immune Microenvironment and Fibroblast Crosstalk in Radiotherapy Combined with Immunotherapy‐Induced Cardiac Fibrosis Based on Single‐Cell Transcriptomic Analysis

Advanced Science, EarlyView.
This study highlights that radioimmunotherapy drives crosstalk between fibroblasts and immune cells (especially macrophages) in the cardiac microenvironment, with IL‐6 as the key mediator, and tocilizumab alleviates cardiac fibrosis by targeting this interplay.
Yuxi Luo, Ying Yu, Zhimin Zeng, Yanxin Chen, Yali Yi, Zhiqin Lu, Fujuan Zeng, Peng Xu, Daya Luo, Leifeng Chen, Anwen Liu   +10 more
wiley   +1 more source